| dc.creator |
Daldal, Hatice.
author
23898 |
|
| dc.creator |
Bardak, Yavuz Kamil,
1966-
thesis advisor
18360 |
|
| dc.creator |
Süleyman Demirel Üniversitesi.
Tıp Fakültesi.
Göz Hastalıkları Anabilim Dalı.
issuing body
14567 |
|
| dc.date |
2011. |
|
| dc.date.accessioned |
2025-02-25T10:49:07Z |
|
| dc.date.available |
2025-02-25T10:49:07Z |
|
| dc.identifier |
http://tez.sdu.edu.tr/Tezler/TT00640.pdf |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/102692 |
|
| dc.description |
This prospective study was aimed to evaluate the effects of intravitreal bevacizumab treatment on best corrected visual acuity (BCVA), central macular thickness (CMT) and central retinal sensitivity in diabetic macular edema. 16 eyes of 12 patients with diabetic macular edema received intravitreal bevacizumab treatment. Standardized ophthalmic evaluation, BCVA, CMT, central retinal sensitivity measurement were performed before therapy, at first week, first month and third month, differences in fluorescein leakage was studied only before therapy and three months after therapy. The mean age was 60,8 ł 5,7. The mean BCVA at baseline, 1 week,1 month, 3 month after injection were 0,12 ł 0,07, 0,15 ł 0,09, 0,22 ł 0,14 and 0,21 ł 0,13, respectively. Best corrected visual acuities increased statistically significant from baseline at 1 week, 1 month and 3 month after injection (p<0,05).The mean CMT at baseline, 1 week, 1 month, 3 month after injection were 589,0 ł 95,3., 496,5 ł 119,4 ., 404,5 ł 101,8 . and 341,1 ł 152,4, respectively. CMT decreased statistically significant from baseline at 1 week, 1 month and 3 month after injection (p<0,05). The mean central retinal sensitivity at baseline, 1 week, 1 month, 3 month after injection were 14,7 ł 5,4 dB, 15,3 ł 4,7 dB, 15,3 ł 4,8 dB, 16,3 ł 5,6 Db respectively. increase of the central retinal sensitivity was observed at first week, first month, third month after injection. +However, central retinal sensitivity increased statistically significant from baseline at 1 week and 3 month after injection (p<0,05). In our study we observed increase in best corrected visual acuity, decrease in central macular thickness and increase central retinal sensitivity after intravitreal bevacizumab treatment for diabetic macular edema. Intravitreal bevacizumab provide a visual, functional and anatomic benefit in eyes with diabetic macular edema in early period. Bevacizumab is effective and safe treatment method in diabetic macular edema. Multicenter, randomized, controlled investigations are required for evaluation of its effects precisely. Keywords : Bevacizumab, Diabetic Macular Edema, Retinal Sensitivity. |
|
| dc.description |
Tez (Uzmanlık)- Süleyman Demirel Üniversitesi, Tıp Fakültesi,Göz Hastalıkları Anabilim Dalı, 2011. |
|
| dc.description |
Kaynakça var. |
|
| dc.description |
This prospective study was aimed to evaluate the effects of intravitreal bevacizumab treatment on best corrected visual acuity (BCVA), central macular thickness (CMT) and central retinal sensitivity in diabetic macular edema. 16 eyes of 12 patients with diabetic macular edema received intravitreal bevacizumab treatment. Standardized ophthalmic evaluation, BCVA, CMT, central retinal sensitivity measurement were performed before therapy, at first week, first month and third month, differences in fluorescein leakage was studied only before therapy and three months after therapy. The mean age was 60,8 ł 5,7. The mean BCVA at baseline, 1 week,1 month, 3 month after injection were 0,12 ł 0,07, 0,15 ł 0,09, 0,22 ł 0,14 and 0,21 ł 0,13, respectively. Best corrected visual acuities increased statistically significant from baseline at 1 week, 1 month and 3 month after injection (p<0,05).The mean CMT at baseline, 1 week, 1 month, 3 month after injection were 589,0 ł 95,3., 496,5 ł 119,4 ., 404,5 ł 101,8 . and 341,1 ł 152,4, respectively. CMT decreased statistically significant from baseline at 1 week, 1 month and 3 month after injection (p<0,05). The mean central retinal sensitivity at baseline, 1 week, 1 month, 3 month after injection were 14,7 ł 5,4 dB, 15,3 ł 4,7 dB, 15,3 ł 4,8 dB, 16,3 ł 5,6 Db respectively. increase of the central retinal sensitivity was observed at first week, first month, third month after injection. +However, central retinal sensitivity increased statistically significant from baseline at 1 week and 3 month after injection (p<0,05). In our study we observed increase in best corrected visual acuity, decrease in central macular thickness and increase central retinal sensitivity after intravitreal bevacizumab treatment for diabetic macular edema. Intravitreal bevacizumab provide a visual, functional and anatomic benefit in eyes with diabetic macular edema in early period. Bevacizumab is effective and safe treatment method in diabetic macular edema. Multicenter, randomized, controlled investigations are required for evaluation of its effects precisely. Keywords : Bevacizumab, Diabetic Macular Edema, Retinal Sensitivity. |
|
| dc.language |
tur |
|
| dc.publisher |
Isparta : SDÜ Tıp Fakültesi, |
|
| dc.subject |
Süleyman Demirel Üniversitesi |
|
| dc.title |
Diyabetik Makula ödeminde intravitreal bevacizumab tedavisinin Santral Makula kalınlığı ve Santral Retina duyarlılığı üzerine etkisi = The effect of Intravitreal Bevacizumab treatment on Central Macular Thickness and Central Retinal Sensitivity in Diabetic Macular edema / |
|
| dc.type |
text |
|